140 related articles for article (PubMed ID: 12918059)
1. IL-18 is produced by prostate cancer cells and secreted in response to interferons.
Lebel-Binay S; Thiounn N; De Pinieux G; Vieillefond A; Debré B; Bonnefoy JY; Fridman WH; Pagès F
Int J Cancer; 2003 Oct; 106(6):827-35. PubMed ID: 12918059
[TBL] [Abstract][Full Text] [Related]
2. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
3. Constitutive expression of IL-18 and IL-18R in differentiated IEC-6 cells: effect of TNF-alpha and IFN-gamma treatment.
Kolinska J; Lisa V; Clark JA; Kozakova H; Zakostelecka M; Khailova L; Sinkora M; Kitanovicova A; Dvorak B
J Interferon Cytokine Res; 2008 May; 28(5):287-96. PubMed ID: 18547159
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression.
Kawashima M; Miossec P
Arthritis Rheum; 2003 Mar; 48(3):631-7. PubMed ID: 12632414
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease.
Salvati VM; MacDonald TT; Bajaj-Elliott M; Borrelli M; Staiano A; Auricchio S; Troncone R; Monteleone G
Gut; 2002 Feb; 50(2):186-90. PubMed ID: 11788557
[TBL] [Abstract][Full Text] [Related]
6. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
Borsellino N; Belldegrun A; Bonavida B
Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines.
Mori S; Murakami-Mori K; Bonavida B
Anticancer Res; 1998; 18(6A):4403-8. PubMed ID: 9891500
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes.
Airoldi I; Raffaghello L; Cocco C; Guglielmino R; Roncella S; Fedeli F; Gambini C; Pistoia V
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):144-54. PubMed ID: 14734463
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of IL-18 receptor in cancer patients: its clinical significance.
Kobashi K; Iwagaki H; Yoshino T; Morimoto Y; Kohka H; Kodama M; Nishibori M; Akagi T; Tanaka N
Anticancer Res; 2001; 21(5):3285-93. PubMed ID: 11848485
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
Okamoto M; Lee C; Oyasu R
Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
[TBL] [Abstract][Full Text] [Related]
11. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Lau KM; LaSpina M; Long J; Ho SM
Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
[TBL] [Abstract][Full Text] [Related]
12. Constitutive expression of interleukin-18 and interleukin-18 receptor mRNA in tumour derived human B-cell lines.
Lorey SL; Huang YC; Sharma V
Clin Exp Immunol; 2004 Jun; 136(3):456-62. PubMed ID: 15147347
[TBL] [Abstract][Full Text] [Related]
13. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
15. Human keratinocytes constitutively produce but do not process interleukin-18.
Mee JB; Alam Y; Groves RW
Br J Dermatol; 2000 Aug; 143(2):330-6. PubMed ID: 10951141
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Lou W; Hou M; de Miguel F; Gerber L; Gao AC
Clin Cancer Res; 2003 Jan; 9(1):370-6. PubMed ID: 12538490
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM
Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667
[TBL] [Abstract][Full Text] [Related]
18. N-3 polyunsaturated fatty acids inhibit IFN-γ-induced IL-18 binding protein production by prostate cancer cells.
Wang X; Breeze A; Kulka M
Cancer Immunol Immunother; 2015 Feb; 64(2):249-58. PubMed ID: 25351720
[TBL] [Abstract][Full Text] [Related]
19. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
20. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production.
Yoshimoto T; Takeda K; Tanaka T; Ohkusu K; Kashiwamura S; Okamura H; Akira S; Nakanishi K
J Immunol; 1998 Oct; 161(7):3400-7. PubMed ID: 9759857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
